Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Dr Harbeck Talks Pertuzumab Plus Trastuzumab in HR-/HER2+ Early Breast Cancer

Nadia Harbeck, MD, PhD, Head of Breast Center, Oncological Therapy and Breast Clinical Trials Unit, University of München, Germany, discusses the biomarker and survival results of a study examining de-escalated neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel for patients with HR-negative/HER2-positive early Breast Cancer.

Advertisement

Advertisement

Advertisement

Advertisement